Close Menu

Jeff Elliott

Nov 09, 2016

Exact Sciences has appointed Jeff Elliott as CFO. He joined the company as vice president of business development and strategy in June and will begin his new role effective immediately. Before joining Exact Sciences, Elliott served as a senior research analyst at Robert W. Baird. Previously in his career, he worked in various positions at Walgreens and Cap Gemini Ernst & Young.

More Like This

Oct 16, 2019

Unilabs: Jos Lamers, Michiel Boehmer, and More

Unilabs has appointed Jos Lamers its executive chairman. He is currently the company's CEO. Additionally, Michiel Boehmer, currently Unilabs' regional director south, will become the president and COO of the firm. He will run Unilabs' daily operations, while Lamers will be responsible for its long-term strategy. 

Boehmer's current responsibilities will be shared by Nicolas Ploquin and Luis Menezes. Ploquin, currently CEO of Unilabs' France will be in charge of part of region south as regional director France, Spain, and Benelux. Menezes, currently CEO of Unilabs Portugal, will also be regional director Portugal, Latin America and the Middle East. 

Christian Rebhan, Unilabs CMO and head of customer excellence, will take over charge of the telemedicine unit from Boehmer and will replace Jacques Herber as head of the operations team. Herber is leaving Unilabs.

Lastly, Martin Schlatter, currently Regional Director Centre, also will become Unilabs' chief commercial officer. 

Oct 15, 2019

Anixa BioSciences: Thomas Schlumpberger

Anixa Biosciences has appointed Thomas Schlumpberger as executive VP, diagnostics. Prior to joining Anixa Schlumpberger held executive roles with several diagnostic companies over the past 20 years, including InVitae, Affymetrix (now Thermo-Fisher Scientific), Inivata, and Singulex. 

Oct 15, 2019

Fluxergy: Ali Tinzali

Fluxergy, an Irvine, California-based developer of point-of-care diagnostics systems, has appointed Ali Tinzali as chief commercial officer. Tinzali joins Fluxergy from Hewlett-Packard, where he led corporate-wide global strategy for healthcare and life sciences. He has also worked in corporate development at Applied Biosystems (now Thermo Fisher Scientific). He also worked for Sony where he helped build a healthcare consumables business that was acquired by Stratec.

Oct 14, 2019

Renalytix AI: Chirag Parikh

AI-based kidney disease diagnostic firm Renalytix AI appointed Chirag Parikh to its board. He is the director of the division of nephrology and the Ronald Peterson professor of medicine at the Johns Hopkins School of Medicine. He has published more than 250 original articles, which have been cited more than 35,000 times. 

Oct 10, 2019

Stilla Technologies: Ruth Szebries

Stilla Technologies has appointed Ruth Szebries as general manager and vice president of commercial operations for its newly established US subsidiary in Beverly, Massachusetts. Szebries will oversee operations in the Americas for the Paris, France-based digital PCR developer. Her previous life science industry experience includes positions at Applied Biosystems and Beckman Coulter, leading the US subsidiaries of BGI and Exiqon, and serving for three years at Qiagen, most recently as that firm's senior director for global market development.

Oct 09, 2019

First Light Diagnostics: Angela Caliendo

First Light Diagnostics has added Angela Caliendo to its clinical advisory board. She is an editor at the Journal of Clinical Microbiology, a board member and fellow of the Infectious Diseases Society of America, and a fellow at the American Academy of Microbiology. She currently is a professor and the executive vice chair of the department of medicine at the Warren Alpert Medical School of Brown University. 

Oct 09, 2019

VolitionRx: Phillip Barnes

VolitionRx has appointed Phillip Barnes to its board, replacing Habib Skaff, who resigned effective Oct. 9. Barnes is a British physician and has been a clinician and clinical manager with the UK National Health Service and related academic institutions. 

Oct 08, 2019

Biodesix: James Jett

Biodesix has appointed James Jett as chief medical officer. Jett previously served as CMO at Oncoimmune. Before Onocimmune, Jett worked as a professor of medicine at the Mayo Medical School and the University of Pittsburgh. Jett has also served as a consultant for the National Cancer Institute and as the editor in chief of the Journal of Thoracic Oncology from 2006 to 2013. 

Oct 04, 2019

Meridian Bioscience: Bryan Baldasare

Meridian has appointed Bryan Baldasare to chief financial officer. He was previously the interim CFO, corporate controller, and treasurer and is currently also the executive vice president and chief accounting officer. Baldasare has been with Meridian since 2000, and before that he was a senior audit manager at Arthur Andersen LLP. 

Sep 30, 2019

Sebia: David Martyr, Benoît Adelus

Sebia has appointed David Martyr as chairman of its board of directors. Alongside Jean-Marc Chermette, CEO of Sebia, Martyr will support the firm's strategic vision in its ongoing next stage of growth, the firm said.

Martyr has served as member of the board of ALDA, the Analytical, Life Sciences & Diagnostics Association, for the past 6 years and is currently a member of the advisory group of Novo Holdings. He was CEO of Tecan from 2012 to 2019. Prior to joining Tecan, Martyr held various executive roles at Leica Microsystems, including group president from 2007 until 2011. He was vice president and group executive of Danaher from 2009 until 2011.

Benoît Adelus is stepping down at Sebia, after serving as CEO from 2008 to 2017 and chairman since 2017.

Sep 26, 2019

Becton Dickinson: Vincent Forlenza, Thomas Polen

Becton Dickinson announced that Vincent Forlenza will retire from his position as of Jan. 28, 2020. Forlenza, who has been with BD for 40 years and has led the company as CEO since 2011, will continue to serve as executive chairman of its board of directors. Thomas Polen, the firm's chief operating officer, will take over as CEO. 

Sep 26, 2019

Cofactor Genomics: Natalie LaFranzo

Cofactor Genomics has promoted Natalie LaFranzo to Vice President of Market Development. She has been with the company for three years. Previously, she held roles in product management at Horizon Discovery and in marketing and communications at Red Rock Labs. LaFranzo will also head Cofactor's new predictive immune modeling center in Cambridge, Massachusetts. The facility will be the company's hub for the research and operations team working with Boston-based pharma, RNA, precision medicine, and immunotherapy companies. 

Sep 26, 2019

Sight Diagnostics: Assi Gol, Noga Eshed-Baror

Sight Diagnostics has appointed Assi Gol as its chief commercial officer and Noga Eshed-Baror as its general US manager.

Before joining the executive team, Gol served on Sight’s advisory board and has supported the company since its founding in 2011. Previously, he served as the data intelligence director at Shop Direct, an online retailer in the UK. He also spent seven years at McKinsey & Company in London and Tel-Aviv.

Eshed-Baror will lead Sight's US efforts, including commercialization and hiring. He is a graduate of the Stanford Business School and brings more than 10 years of business experience, having led projects at both Google and McKinsey. 

Sep 25, 2019

Myriad Genetics: Colleen Reitan, Lee Newcomer

Myriad Genetics has elected Colleen Reitan and Lee Newcomer to its board of directors.

Reitan has spent more than 32 years working in the Blue Cross Blue Shield system, most recently as president of plan operations for Health Care Service Corporation (HCSC), a health plan covering 16 million lives. Prior to BCBS, Reitan held several roles of increasing responsibility including executive VP and chief operating officer for HCSC and president and chief operating officer of BCBS of Minnesota. She currently serves on the boards of Alnylam Pharmaceuticals and Cricket Health.

Newcomer is a board-certified oncologist who most recently served as senior VP of oncology and genetics for UnitedHealthcare. Previously, he was chief medical officer and senior VP of health policy and strategy at UnitedHealth Group. He also served as chief medical officer at Vivius. Newcomer currently serves on the board of Cellworks Group and Intervention Insights.

Sep 25, 2019

First Light Diagnostics: Joanne Spadoro

Joanne Spadoro has joined First Light Diagnostics as vice president of R&D and regulatory affairs. Spadoro has more than 20 years of experience in the in vitro diagnostics space, the Chelmsford, Massachusetts-based company said. According to her LinkedIn profile, she was chief commercial officer at T2 Biosystems, CSO and VP of worldwide operations at Immucor, and senior VP of global development and operations at Roche Molecular Systems.